Table.1.
The Descriptive summary of global landscape of malaria sporozoite challenge studies conducted from 1990 to 2018
| Characteristics | Number of studies |
|---|---|
| Sporozoite challenge study based on purpose | |
| Sporozoite infectivity studies | 19 |
| Malaria vaccine efficacy studies | 44 |
| Drug evaluation (chemoprophylaxis) | 5 |
| Acquired immunity assessment | 2 |
| Country trial conducted | |
| USA | 31 |
| Netherlands | 11 |
| UK | 9 |
| Germany | 3 |
| Colombia | 5 |
| Spain | 2 |
| Tanzania | 2 |
| Kenya | 3 |
| Gabon | 1 |
| Equatorial Guinea | 1 |
| Mali | 2 |
| Allocation to treatment | |
| Randomized placebo-controlled | 39 |
| Non-randomized controlled | 16 |
| Open-label | 2 |
| Not known | 9 |
| Masking type | |
| Double-blind | 26 |
| Single-blind | 6 |
| Open-label | 35 |
| Not known | 3 |
| Intervention model | |
| Parallel assignment | 54 |
| Single group assignment | 8 |
| Factorial assignment | 2 |
| Not known | 5 |
| Phase of study | |
| Phase 1 | 32 |
| Phase 1/2a | 20 |
| Phase 2 | 6 |
| Not applicable | 6 |
| Not known | 5 |
| Sporozoite challenge study type | |
| Mosquito bite based | 52 |
| PfSPZ challenge based | 18 |
| Strain/clone of plasmodium used | |
| PfNF54 | 29 |
| Pf3D7 | 24 |
| PfNF166.C8 | 3 |
| PfNF135.C10 | 3 |
| Pf7G8 | 4 |
| Pv clinical isolate | 7 |
| Mosquito species used | |
| A.stephensi | 44 |
| A.albimanus | 5 |
| A. gambiae | 1 |
| A.dirus | 1 |